AMGEN INC (AMGN) Form 8-K — Nov 3, 2026
Amgen reported Q3 2026 total revenues of $10.4 billion, up 8% year over year, with product sales growth driven by volume across 17 products annualizing at more than $1 billion each. GAAP EPS rose 19% to $7.08 and non-GAAP EPS rose 14% to $6.45. Growth was led by Repatha (+37%), EVENITY (+39%), UPLIZNA (+191%) and IMDELLTRA (+128%), but legacy bone drugs Prolia and XGEVA fell 45% and 47% respectively as biosimilars launched globally. Free cash flow declined to $3.7 billion from $4.2 billion on working capital timing.
Key figures
- Eps
- 7.08
- Revenue
- 10365000000
- Guidance
- FY2026 total revenues $38.9B-$39.7B; GAAP EPS $18.34-$19.28; non-GAAP EPS $22.90-$23.70; capex ~$2.6B; share repurchases not to exceed $3.0B
- Net Income
- 3864000000
- Total Debt
- 54000000000
- Revenue Yoy
- 8%
- Total Assets
- 96048000000
- Cash Position
- 13190000000
- Shares Outstanding
- 541000000
- Non gaap eps
- $6.45 (up 14% YoY)
- Product sales
- $9,883M (up 8%)
- Xgeva decline
- -47% to $288M on biosimilars
- Free cash flow
- $3.7B vs $4.2B prior year
- Prolia decline
- -45% to $632M on biosimilars
- Uplizna growth
- +191% to $451M
- Imdelltra growth
- +128% to $406M
- Gaap operating margin
- 37.5% (up 9.9 pts)
- Q3 dividend per share
- $2.52 (up 6% YoY)
- Non gaap operating margin
- 47.3%
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.